IRLAB Therapeutics' Linepemat Preclinical Research Is Published in Peer-Reviewed Journal

PUBT · 3d ago
IRLAB Therapeutics' Linepemat Preclinical Research Is Published in Peer-Reviewed Journal
  • IRLAB Therapeutics published preclinical research underpinning linepemat (IRL757), its investigational apathy treatment, in the peer-reviewed journal Bioorganic & Medicinal Chemistry Letters.
  • Researchers selected linepemat for increasing cortical dopamine and noradrenaline while avoiding mechanisms associated with dependence; positive preclinical results supported human trials.
  • The candidate is undergoing the Otsuka-funded Phase Ib LIFT-PD study in patients with Parkinson's disease and apathy.
  • Otsuka has funded development through proof of concept since 2024; first dosing in February 2026 triggered a USD 3 million milestone payment.
  • Initial LIFT-PD results are expected in mid-2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IRLAB Therapeutics AB published the original content used to generate this news brief on October 20, 2026, and is solely responsible for the information contained therein.